Significance of cyclooxygenase-2 in oncogenesis

1. Adams J.M., Cory S.: Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007, 19, 488–496.10.1016/j.coi.2007.05.004Search in Google Scholar

2. Arenas C., Peña L., Granados-Soler J.L., Pérez-Alenza M.D.: Adjuvant therapy for highly malignant canine mammary tumours: Cox-2 inhibitor versus chemotherapy: a case-control prospective study. Vet Rec 2016, 179, 125.10.1136/vr.103398Search in Google Scholar

3. Baeriswyl V., Christofori G.: The angiogenic switch in carcinogenesis. Sem Cancer Biol 2009, 19, 329–337.10.1016/j.semcancer.2009.05.003Search in Google Scholar

4. Basu G.D., Tinder T.L., Bradley J.M., Tu T., Hattrup C.L., Pockaj B.A., Mukherjee P.: Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006, 177, 2391–2402.10.4049/jimmunol.177.4.2391Search in Google Scholar

5. Becht E., Aurélien de Reyniès A., Wolf H., Fridman W.H.: Integrating tumor microenvironment with cancer molecular classifications. Genome Med 2015, 7, 115.10.1186/s13073-015-0241-4Search in Google Scholar

6. Bosman F.T., Visser B.C., van Oeveren J.: Apoptosis: pathophysiology of programmed cell death. Pathol Res Pract 1996, 192, 676–683.10.1016/S0344-0338(96)80089-6Search in Google Scholar

7. Burdan F., Chałas A., Szumiło J.: Cyclooxygenase and prostanoids – biological implications. Post Hig Med Dośw 2006, 60, 129–141.Search in Google Scholar

8. Cancedda S., Sabattini S., Bettini G., Leone V.F., Laganga P., Rossi F., Terragni R., Gnudi G., Vignoli M.: Combination of radiation therapy and firocoxib for the treatment of canine nasal carcinoma. Vet Radiol Ultrasound 2015, 56, 335–343.10.1111/vru.1224625703137Search in Google Scholar

9. Carmeliet P.: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 63, 89–95.Search in Google Scholar

10. Carvalho M.I., Pires I., Prada J., Ferreira A.F., Queiroga F.L.: Positive interplay between CD3+ T-lymphocytes and concurrent COX-2/EGFR expression in canine malignant mammary tumors. Anticancer Res 2015, 35, 2915–2920.Search in Google Scholar

11. Carvalho S., Stoll A.L., Priestnall S.L., Suarez-Bonnet A., Rassnick K., Lynch S., Schoepper I., Romanelli G., Buracco P., Atherton M., de Merlo E.M., Lara-Garcia A..: Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy. Vet Comp Oncol 2017, 15, 1280–1294.10.1111/vco.1226427578604Search in Google Scholar

12. Cetin M., Buyukberber S., Demir M., Sari I., Sari I., Deniz K., Eser B., Altuntaz F., Camci C., Ozturk A., Turgut B., Vural O., Unal A.: Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 2005, 80, 169–173.10.1002/ajh.2046016247750Search in Google Scholar

13. Chandrasekharan N.V., Dai H., Roos K.L.T., Evanson N.K., Tomsik J., Elton T.S., Simmons D.L.: COX-3, a cyclooxygenase -1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002, 99, 13926–13931.10.1073/pnas.16246869912979912242329Search in Google Scholar

14. Chandrasekharan N.V., Simmons D.L.: The cyclooxygenases. Genome Biol 2004, 5, 241.10.1186/gb-2004-5-9-24152286415345041Search in Google Scholar

15. Chen S.F., Liou J.Y., Huang T.Y., Lin Y.S., Yeh A.L., Tam K., Tsai T.H., Wu K.K., Shyne S.K.: Caveolin-1 facilitates cyclooxygenase-2 protein degradation. J Cell Biochem 2010, 109, 356–362.10.1002/jcb.2240719960513Search in Google Scholar

16. Cheng H.F., Harris R.C.: Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005, 11, 1795–1804.10.2174/138161205376492215892676Search in Google Scholar

17. Chung A.S, Lee J., Ferrara N.: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10, 505–514.10.1038/nrc286820574450Search in Google Scholar

18. Cok S.J., Morrison A.R.: The 3’-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 76, 23179–23185.10.1074/jbc.M00846120011294846Search in Google Scholar

19. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A.M.: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399, 601–605.10.1038/2122410376603Search in Google Scholar

20. Dogne J.M., Supuran C.T., Pratico D.: Adverse cardiovascular effects of the coxibs. J Med Chem 2005, 48, 2251–2257.10.1021/jm040205915801815Search in Google Scholar

21. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G.J., Sharma S., Huang M., Pold M., Batra R.K., Dubinett S.M.: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001, 276, 20809–20812.10.1074/jbc.C100140200147188211320076Search in Google Scholar

22. Dohadwala M., Yang S.C., Luo J., Sharma S., Batra R.K., Huang M., Lin Y., Goodglick L., Krysan K., Fishbein M.C., Hong L., Lai C., Cameron R.B., Gemmill R.M., Drabkin H.A., Dubinett S.M.: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and Snail in non-small cell lung cancer. Cancer Res 2006, 66, 5338–5345.10.1158/0008-5472.CAN-05-363516707460Search in Google Scholar

23. Dome B., Hendrix M.J., Paku S., Tovari J., Timar J.: Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007, 170, 1–15.10.2353/ajpath.2007.060302176270917200177Search in Google Scholar

24. Doré M.: Cyclooxygenase-2 expression in animal cancers. Vet Pathol 2011, 48, 254–265.10.1177/0300985810379434Search in Google Scholar

25. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N.: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183–1188.10.1016/0016-5085(94)90246-1Search in Google Scholar

26. Ebos J.M., Kerbel R.S.: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011, 8, 210–221.10.1038/nrclinonc.2011.21454033621364524Search in Google Scholar

27. Edelman M.J., Watson D., Wang X., Morrison C., Kratzke R.A., Jewell S., Hodgson L., Mauer A.M., Gajra A., Masters G.A., Bedor M., Vokes E.E., Green M.J.: Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008, 26, 848–855.10.1200/JCO.2007.13.808118281656Search in Google Scholar

28. Eliceiri B.P., Cheresh D.A.: The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999, 103, 1227–1230.10.1172/JCI686940836010225964Search in Google Scholar

29. Elmore S.: Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35, 495–516.10.1080/01926230701320337211790317562483Search in Google Scholar

30. Folkman J.: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1, 27–31.10.1038/nm0195-277584949Search in Google Scholar

31. Fridman W.H., Pagès F., Sautès-Fridman C., Galon J.: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12, 298–306.10.1038/nrc324522419253Search in Google Scholar

32. Fux R., Schwab M., Thon K.P., Gleiter C.H., Fritz P.: Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005, 11, 4754–4760.10.1158/1078-0432.CCR-04-258616000571Search in Google Scholar

33. Gerl R., Vaux D.L.: Apoptosis in the development and treatment of cancer. Carcinogenesis 2005, 26, 263–270.10.1093/carcin/bgh28315375012Search in Google Scholar

34. Giles F.J., Kantarjian H.M., Bekele B.N., Cortes J.E., Federl S., Thomas D.A., Manshuri T., Rogers A., Keating M.J., Talpaz M., O’Brien S., Albitar M.: Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 2002, 119, 38–45.10.1046/j.1365-2141.2002.03784.x12358901Search in Google Scholar

35. Gos M., Miłoszewska J., Przybyszewska M.: Epithelialmesenchymal transition in cancer progression. Post Biochem 2009, 55, 121–128.Search in Google Scholar

36. Greenhough A., Smartt H.J.M., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A.: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30, 377–386.10.1093/carcin/bgp01419136477Search in Google Scholar

37. Gregório H., Raposo T., Queiroga F.L., Pires I., Pena L., Prada J.: High COX-2 expression in canine mast cell tumours is associated with proliferation, angiogenesis and decreased overall survival. Vet Comp Oncol 2017, 15, 1382–1392.10.1111/vco.1228028467670Search in Google Scholar

38. Gregório H., Raposo T.P., Queiroga F.L., Prada J., Pires I.: Investigating associations of cyclooxygenase-2 expression with angiogenesis, proliferation, macrophage and T-lymphocyte infiltration in canine melanocytic tumours. Melanoma Res 2016, 26, 338–347.10.1097/CMR.000000000000026227105172Search in Google Scholar

39. Grimes K.R., Warren G.W., Fang F., Xu Y., St Clair W.H.: Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep 2006, 16, 771–776.10.3892/or.16.4.771Search in Google Scholar

40. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N.: Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002, 168, 2255–2263.10.4049/jimmunol.168.5.225511859113Search in Google Scholar

41. Hinz B., Brune K.: Cyclooxygenase-2 - 10 years later. J Pharm Exp Therap 2001, 300, 367–375.10.1124/jpet.300.2.36711805193Search in Google Scholar

42. Holmgaard R.B., Zamarin D., Gasmi B., Munn D.H., Allison J.P., Merghoub T., Wolchok J.D.: Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep 2015, 13, 412–424.10.1016/j.celrep.2015.08.077501382526411680Search in Google Scholar

43. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S.: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275, 11397–11403.10.1074/jbc.275.15.1139710753955Search in Google Scholar

44. Huang M., Stolina M., Sharma S., Mao J.T., Zhu L., Miller P.W., Wollman J., Herschman H., Dubinett S.M.: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998, 58, 1208–1216.Search in Google Scholar

45. Ishikawa T., Herschman H.R.: Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010, 31, 729–736.10.1093/carcin/bgq002284709120061361Search in Google Scholar

46. Iturriaga M.P., Oaredes R., Arias J.I., Torres C.G.: Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells. Oncol Lett 2017, 14, 2198–2206.10.3892/ol.2017.6400553018528781660Search in Google Scholar

47. Jackson L.M., Wu K.C., Mahida Y.R., Jenkins D., Hawkey C.J.: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000, 47, 762–770.10.1136/gut.47.6.762172813311076873Search in Google Scholar

48. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C.: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008, 68, 7750–7759.10.1158/0008-5472.CAN-07-668918829529Search in Google Scholar

49. Kim D., Kim S., Koh H., Yoon S.O., Chung A.S., Cho K.S., Chung J.: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 2001, 15, 1953–1962.10.1096/fj.01-0198com11532975Search in Google Scholar

50. Komhoff M., Grone H.J., Klein T., Seyberth H.W., Nursing R.M.: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997, 272, F460–F468.10.1152/ajprenal.1997.272.4.F4609140046Search in Google Scholar

51. Kozłowski W., Szacikowska E.: Manysided herceptin action in HER2 overexpressing cells. Współcz Onkol 2001, 5, 254–259.Search in Google Scholar

52. Krajewska W.M, Masłowska I.: Caveolin, caveolae and neoplastic transformation. Post Biol Kom 31, 2004, 22, 85–99.Search in Google Scholar

53. Krysan K., Dalwadi H., Sharma S., Pold M., Dubinett S.: Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004, 64, 6359–6362.10.1158/0008-5472.CAN-04-168115374938Search in Google Scholar

54. Krześlak A.: Akt kinase: a key regulator of metabolism and progression of tumors. Post Hig Med Dośw 2010, 64, 490–503.Search in Google Scholar

55. Lall S.: Activating apoptosis. Nat Struct Mol Biol 2009, 16, 614.10.1038/nsmb0609-61419491939Search in Google Scholar

56. Lazarus M., Eguchi N., Matsumoto S., Nagata N., Yano T., Killian G.J., Urade Y.: Species-specific expression of microsomal prostaglandin E synthase-1 and cyclooxygenases in male monkey reproductive organs. Prostag Leukotr Ess 2004, 71, 233–240.10.1016/j.plefa.2004.03.01815301794Search in Google Scholar

57. Lee J.W., Bae S.H., Jeong J.W., Kim S.H., Kim K.W.: Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions. Exp Mol Med 2004, 36, 1–12.10.1038/emm.2004.115031665Search in Google Scholar

58. Ling F.C., Baldus S.E., Khochfar J., Xi H., Neiss S., Brabender J., Metzger R., Drebber U., Dienes H.P., Bollschweiler E., Hoelscher A.H., Schneider P.M.: Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett’s metaplasia and progression to cancer. Histopathology 2007, 50, 203–209.10.1111/j.1365-2559.2007.02576.x17222248Search in Google Scholar

59. Mantovani A., Allavena P., Sica A., Balkwill F.: Cancer-related inflammation. Nature 2008, 454, 436–444.10.1038/nature07205Search in Google Scholar

60. Millanta F., Asproni P., Canale A., Citi S., Poli A.: COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours. Vet Comp Oncol 2016, 14, 270–280.10.1111/vco.12096Search in Google Scholar

61. Misra S., Obeid L.M., Hannun Y.A., Minamisawa S., Berger F.G., Markwald R.R., Toole B.P., Ghatak S.: Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem 2008, 283, 14335–14344.10.1074/jbc.M703811200Search in Google Scholar

62. Mrena J., Wiksten J.-P., Kokkola A., Nordling S., Ristimaki A., Haglund C.: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010, 31, 1–7.10.1007/s13277-009-0001-4Search in Google Scholar

63. Mukherjee P., Basu G.D., Tinder T.L., Subramani D.B., Bradley J.M., Arefayene M., Skaar T., De Petris G.: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009, 182, 216–224.10.4049/jimmunol.182.1.216Search in Google Scholar

64. Nakata E., Mason K.A., Hunter N., Husain A., Raju U., Liao Z., Ang K.K., Milas L.: Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys 2004, 58, 369–375.10.1016/j.ijrobp.2003.09.061Search in Google Scholar

65. O’Neill G.P., Ford-Hutchinson A.W.: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 330, 156–160.10.1016/0014-5793(93)80263-TSearch in Google Scholar

66. Ogino S., Kirkner G.J., Nosho K., Irahara N., Kure S., Shima K., Hazra A., Chan A.T., Dehari R., Giovannucci E.L., Fuchs C.S.: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008, 14, 8221–8227.10.1158/1078-0432.CCR-08-1841Search in Google Scholar

67. Ohsawa M., Fukushima H., Ikura Y., Inoue T., Shirai N., Sugama Y., Suekane T., Kitabayashi C., Nakamae H., Hino M., Ueda M.: Expression of cyclooxygenase-2 in Hodgkin’s lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma 2006, 47, 1863–1871.10.1080/10428190600685442Search in Google Scholar

68. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M.: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803–809.10.1016/S0092-8674(00)81988-1Search in Google Scholar

69. Pasinetti G.M.: Cyclooxygenase and inflammation in Alzheimer’s disease: experimental approaches and clinical intervention. J Neurosci Res 1998, 54, 1–6.10.1002/(SICI)1097-4547(19981001)54:1<1::AID-JNR1>3.0.CO;2-MSearch in Google Scholar

70. Remark R., Alifano M., Cremer I., Lupo A., Dieu-Nosjean M.C., Riquet M., Crozet L., Ouakrim H., Goc J., Cazes A., Fléjou J.F., Gibault L., Verkarre V., Régnard J.F., Pagès O.N., Oudard S., Mlecnik B., Sautès-Fridman C., Fridman W.H., Damotte D.: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013, 19, 4079–4091.10.1158/1078-0432.CCR-12-3847Search in Google Scholar

71. Richardsen E., Uglehus R.D., Due J., Busch C., Busund L.-T.: COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol 2010, 34, 316–322.10.1016/j.canep.2010.03.019Search in Google Scholar

72. Riedl K., Krysan K., Pold M., Dalwadi H., Heuze-Vourc’h N., Dohadwala M., Liu M., Cui X., Figlin R., Mao J.T., Strieter R., Sharma S., Dubinett S.M.: Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 2004, 7, 169–184.10.1016/j.drup.2004.04.003Search in Google Scholar

73. Rizzo M.T.: Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011, 412, 671–687.10.1016/j.cca.2010.12.026Search in Google Scholar

74. Salvado M.D., Alfranca A., Haeggstrom J.Z., Redondo J.M.: Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med 2012, 18, 233–243.10.1016/j.molmed.2012.02.002Search in Google Scholar

75. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P.: Augmented expression of cyclooxygenase-2 in human artherosclerotic lesions. Am J Pathol 1999, 155, 1281–1291.10.1016/S0002-9440(10)65230-3Search in Google Scholar

76. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S.: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67, 4507–4513.10.1158/0008-5472.CAN-06-4174Search in Google Scholar

77. Sitarz R., Leguit R.J., de Leng W.W., Morsink F.H., Polkowski W.P., Maciejewski R., Offerhaus G.J., Milne A.N.: Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines. Cell Oncol 2009, 31, 475–485.10.1155/2009/634178Search in Google Scholar

78. Slater D., Berger L., Newton R., Moore G., Bennett P.: The relative abundance of type 1 to type 2 cyclooxygenase mRNA in human amnion at term. Biochem Biophys Res Commun 1994, 198, 304–308.10.1006/bbrc.1994.1043Search in Google Scholar

79. Sobczyńska-Rak A., Silmanowicz P., Polkowska I.: Tumor angiogenesis – factors influencing the development of a tumor vascular network and assessment of neoangiogenesis in histopathological samples. Med Weter 2016, 72, 542–548.10.21521/mw.5563Search in Google Scholar

80. Solinas G., Marchesi F., Garlanda C., Mantovani A., Allavena P.: Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010, 29, 243–248.10.1007/s10555-010-9227-2Search in Google Scholar

81. Somiari S.B., Shriver C.D., Heckman C., Olsen C., Hu H., Jordan R., Arciero C., Russell S., Garguilo G., Hooke J., Somiari R.I.: Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett 2006, 233, 98–107.10.1016/j.canlet.2005.03.003Search in Google Scholar

82. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T.: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89, 2637–2645.10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-BSearch in Google Scholar

83. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000, 164, 361–370.10.4049/jimmunol.164.1.361Search in Google Scholar

84. Svensson C.I., Yaksh T.L.: The spinal phospholipasecyclooxygenase-prostanoid cascade in nociceptive processing. Annu Rev Pharmacol Toxicol 2002, 42, 553–583.10.1146/annurev.pharmtox.42.092401.143905Search in Google Scholar

85. Swidzińska E., Naumnik W., Chyczewska E.: Angiogenesis and neoangiogenesis – the role in lung cancer and other tumors. Pneumonol Alergol Pol 2006, 74, 414–420.10.5603/ARM.28026Search in Google Scholar

86. Szala S., Jarosz M.: Tumor blood vessels. Post Hig Med Dośw 2011, 65, 437–446.10.5604/17322693.951193Search in Google Scholar

87. Tamura D., Saito T., Murata K., Kawashima M., Asano R.: Celecoxib exerts antitumor effects in canine mammary tumor cells via COX-2-independent mechanisms. Int J Oncol 2015, 46, 1393–1404.10.3892/ijo.2015.2820Search in Google Scholar

88. Thamm D.H., Ehrhart E.J. III, Charles J.B., Elce Y.A.: Cyclooxygenase-2 expression in equine tumors. Vet Pathol 2008, 45, 825–828.10.1354/vp.45-6-825Search in Google Scholar

89. Tsatsanis C., Androulidaki A., Venihaki M., Margioris A.N.: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38, 1654–1661.10.1016/j.biocel.2006.03.021Search in Google Scholar

90. Vahidi R., Safi S., Farsinejad A., Panahi N.: Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells. Cell Mol Biol (Noisy-le-grand). 2015, 61, 22–28.Search in Google Scholar

91. Veikkola T., Karkkainen M., Classon-Welsh L., Alitalo K.: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60, 203–212.Search in Google Scholar

92. Wada M., Saunders T.L., Morrow J., Milne G.L., Walker K.P., Dey S.K., Brock T.G., Opp M.R., Aronoff D.M., Smith W.L.: Two pathways for cyclooxygenase-2 protein degradation in vivo. J Biol Chem 2009, 284, 30742–30753.10.1074/jbc.M109.052415Search in Google Scholar

93. Wideł M.S., Wideł M.: Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Post Hig Med Dośw 2006, 60, 453–470.Search in Google Scholar

94. Williams C.S., Mann M., DuBois R.N.: The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999, 18, 7908–7916.10.1038/sj.onc.1203286Search in Google Scholar

95. Wong R.S.: Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011, 30, 87.10.1186/1756-9966-30-87Search in Google Scholar

96. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F.: Expression of mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11, 371–386.10.1016/0896-6273(93)90192-TSearch in Google Scholar

97. Yuan A., Yu C.J., Shun C.T., Luh K.T., Kuo S.H., Lee Y.C., Yang P.C.: Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005, 115, 545–555.10.1002/ijc.2089815704107Search in Google Scholar

98. Zeng Q., McCauley L.K., Wang C.Y.: Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 2002, 277, 50137–50142.10.1074/jbc.M20895220012393863Search in Google Scholar

99. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., De Marzo A.M.: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004, 215, 1–20.10.1016/j.canlet.2004.06.01415374627Search in Google Scholar